These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 23782077

  • 21. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
    Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M.
    Am J Hematol; 2017 Mar; 92(3):286-291. PubMed ID: 28052413
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency.
    Usmanov RI, Zueva EB, Silverberg DS, Shaked M.
    J Nephrol; 2008 Mar; 21(2):236-42. PubMed ID: 18446719
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease.
    Nordfjeld K, Andreasen H, Thomsen LL.
    Drug Des Devel Ther; 2012 Mar; 6():43-51. PubMed ID: 22419860
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
    Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J.
    Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P, Rumyantsev V.
    Arzneimittelforschung; 2010 Nov; 60(6a):373-85. PubMed ID: 20648929
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Comparison of iron isomaltoside ferumoxytol with iron sucrose for iron deficiency anemia: a meta-analysis of randomized controlled trials.
    Shi L, Zhao Y, Rao A.
    Afr Health Sci; 2023 Sep; 23(3):205-212. PubMed ID: 38357109
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model.
    Toblli JE, Cao G, Oliveri L, Angerosa M.
    Arzneimittelforschung; 2011 Sep; 61(10):553-65. PubMed ID: 22164963
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE, Lombraña A, Duarte P, Di Gennaro F.
    J Am Coll Cardiol; 2007 Oct 23; 50(17):1657-65. PubMed ID: 17950147
    [Abstract] [Full Text] [Related]

  • 40. Iron replacement and supplementation in patients with chronic kidney disease.
    Wazny LD, Raymond CB.
    CANNT J; 2011 Oct 23; 21(4):26-30; quiz 31-2. PubMed ID: 22324122
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.